Furthermore, human cancer cell lines treatment with growth hormone-releasing hormone (GHRH) antagonist MIA-602 show an increase in Cav-1 expression with a consequence of down-modulation of NF-κB [181]. The gene discussed is GHRH; the disease is cancer.